key: cord-0879105-rjb6fpnt authors: Milliere, Laurine; Engelmann, Ilka; Tinez, Claire; Bouarouro, Youssef; Ouafi, Mahdi; Lazrek, Mouna; Prevost, Brigitte; Hober, Didier; Bocket, Laurence; Alidjinou, Enagnon Kazali title: Stool samples versus nasopharyngeal specimens for the initial diagnosis of SARS‐CoV‐2 infection date: 2021-03-05 journal: J Med Virol DOI: 10.1002/jmv.26923 sha: 18374cf6a78fa55061b2563959e750991f3662ad doc_id: 879105 cord_uid: rjb6fpnt Some practionners are tempted to use stool samples, as an easier alternative to nasopharyngeal specimens (NPS) for initial diagnosis of COVID‐19. This report shows that stool samples cannot be used as alternative to NPS for the initial diagnosis of COVID‐19, but as an additional tool in patients presenting with gastrointestinal symptoms. This article is protected by copyright. All rights reserved. We read with a great interest the article by Fumian TM et al, entitled "SARS-CoV-2 RNA detection in stool samples from acute gastroenteritis cases, Brazil" and published in the Journal of Medical Virology on January 2021 (Fumian et al., 2021) . Indeed, their work and several others have reported the detection SARS-CoV-2 RNA in the feces of COVID-19 patients, which had suggested the possibility of SARS-CoV-2 transmission via the fecal-oral route. Clinical spectrum of the disease can be very heterogeneous (Guan et al., 2020) , and rapid and accurate diagnosis is essential for, early reporting, early quarantine, early treatment, and cutting off epidemic transmission. Gastrointestinal symptoms such as diarrhea, abdominal pain, and vomiting have been reported in patients with COVID-19, and have been correlated with SARS-CoV-2 RNA detection in stool samples of these patients (Cheung et al., 2020) . With such data, some practionners are tempted to use This article is protected by copyright. All rights reserved. Article stool samples, as an easier alternative to nasopharyngeal samples (NPS) for initial diagnosis of COVID-19. We here describe a comparison between stool and nasopharyngeal specimens for the initial detection of SARS-CoV-2 RNA in patients with suspected COVID-19. This retrospective analysis included consecutive patients who underwent COVID-19 testing on a NPS, with a stool sample collected within +/-48 hours of NPS collection. Samples were tested using a SARS-CoV-2 RT-PCR inhouse assay developped by the Institut Pasteur Paris, or the Realstar SARS-CoV2 RT-PCR Kit1.0 (Altona Diagnostics). Data were compared using the Man-Whitney test, or the Fisher's exact test. This study was based on medical records, in strict compliance with the French reference methodology MR-004 established by French National Commission on Informatics and Liberties (CNIL), and approved by the Institutional data protection authority of CHU Lille. A total of 197 patients were included in this study. The female/male sex-ratio was 0.93, and the median age was 53 years old (range from 0 to 96 years old). Most of stool samples (62.4%) were collected the same day as the NPS, and the others within +/-48 hours. As shown in Figure 1 , SARS-CoV-2 RNA was detected in 27 NPS (13.7%). Only 12 fecal samples corresponding to these NPS were found positive, giving a positive agreement of 44.4%. The median time since symptoms onset was similar in patients with a negative result in stools as compared to those with a This article is protected by copyright. All rights reserved. On the other hand, the negative agreement was 98.8%. Indeed, virus RNA was detected in 2 stool samples among those corresponding to negative NPS. In one patient, the stool sample was collected 2 days post symptoms onset, and the COVID-19 diagnosis was confirmed with a positive sputum sample. In the other patient, the stool sample was collected 20 days post symptoms onset. No other respiratory sample was available, but anti-SARS-CoV-2 IgM and IgA antibodies were detected in a serum sample collected 4 days later. Our results confirm that SARS-CoV-2 RNA is detected in stool only in a proportion of patients with positive respiratory samples. In their recent metaanalysis, Cheung KS et al reported that virus RNA was detected in stool samples from 48.1% of COVID-19 patients during the course of the illness, even in stool collected after respiratory samples tested negative (Cheung et al., 2020) . The duration of SARS-CoV-2 detection was reported to be significantly longer in stool samples than in respiratory samples (Zheng et al., 2020) et can reach up to 47 days after first symptoms onset (Wu et al., 2020) . This article is protected by copyright. All rights reserved. However, viral RNA was detectable in the stool of only 15.3% of patients on presentation (Cheung et al., 2020) . Otherwise, it's currently well known that NPS can yield false negative results, probably due to sample quality, or to the time of collection, and this type of sample should be repeated or supplemented with other types of samples such as LRT specimens in patients with pneumonia, or stool samples in patients with gastrointestinal symptoms In conclusion, stool samples cannot be used as alternative to NPS for the initial diagnosis of COVID-19; however they can represent an additional tool in patients presenting with gastrointestinal symptoms. Figure Figure 1 . Detection of SARS-CoV-2 RNA in stool and nasopharyngeal specimens Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis SARS-CoV-2 RNA detection in stool samples from acute gastroenteritis cases, Brazil Clinical Characteristics of Coronavirus Disease 2019 in China Prolonged presence of SARS-CoV-2 viral RNA in faecal samples Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China The authors thank the teams involved in the response against COVID-19 at the University Hospital of Lille, France